Model-Based Cost-Effectiveness Analyses for the Treatment of Acute Stroke Events: A Review and Summary of Challenges

被引:17
|
作者
Earnshaw, Stephanie R. [1 ]
Wilson, Michele [1 ]
Mauskopf, Josephine [1 ]
Joshi, Ashish V. [2 ]
机构
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Novo Nordisk Inc, Princeton, NJ USA
关键词
cost-effectiveness analysis; decision analysis; stroke outcomes; systematic review; TISSUE-PLASMINOGEN ACTIVATOR; ACUTE ISCHEMIC-STROKE; QUALITY-OF-LIFE; RESOURCE UTILIZATION; ECONOMIC-MODEL; FACTOR-VII; CARE; THROMBOLYSIS; THERAPY; UTILITY;
D O I
10.1111/j.1524-4733.2008.00467.x
中图分类号
F [经济];
学科分类号
02 ;
摘要
To summarize the methodological approaches used in published decision-analytic models evaluating interventions for acute stroke treatment, to highlight key components of decision-analytic models of stroke treatment, and to discuss challenges for developing stroke decision models. A review of the published literature was performed using Medline, to identify studies involving mathematical decision models to evaluate interventions for acute stroke treatment. Articles were analyzed to determine key components of a stroke model and to note areas in which data are lacking. We identified 13 published models of acute stroke treatment. These models typically possessed a short-term treatment module and a long-term post-treatment module. The following aspects of economic modeling were found to be relevant for developing a stroke model: modeling approach and health state; health state transition probabilities; estimation of short-term, long-term, and indirect costs; health state utilities; poststroke mortality; time horizon; model validation; and estimation of parameter uncertainty. Data gaps have limited the development of economic models in stroke to date. In order to more accurately assess the long-term incremental impact of a new treatment of stroke, future research is needed to address these data gaps. We recommend that the complexity of models for examining the cost-effectiveness of an acute stroke treatment be kept to a minimum such that it can incorporate the currently available data without making a large number of assumptions around the data.
引用
收藏
页码:507 / 520
页数:14
相关论文
共 50 条
  • [1] Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Myeloid Leukaemia: A Review and Summary of Challenges
    Marsh, Kevin
    Xu, Peng
    Orfanos, Panagiotis
    Benedict, Agnes
    Desai, Kamal
    Griebsch, Ingolf
    PHARMACOECONOMICS, 2014, 32 (09) : 853 - 864
  • [2] Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Myeloid Leukaemia: A Review and Summary of Challenges
    Kevin Marsh
    Peng Xu
    Panagiotis Orfanos
    Agnes Benedict
    Kamal Desai
    Ingolf Griebsch
    PharmacoEconomics, 2014, 32 : 853 - 864
  • [3] Model-Based Cost-Effectiveness Analyses for Prostate Cancer ChemopreventionA Review and Summary of Challenges
    Stephanie R. Earnshaw
    Andrew P. Brogan
    Cheryl L. McDade
    PharmacoEconomics, 2013, 31 : 289 - 304
  • [4] Model-Based Cost-Effectiveness Analyses for Prostate Cancer Chemoprevention A Review and Summary of Challenges
    Earnshaw, Stephanie R.
    Brogan, Andrew P.
    McDade, Cheryl L.
    PHARMACOECONOMICS, 2013, 31 (04) : 289 - 304
  • [5] A systematic review of cost-effectiveness analyses for the treatment of stroke
    Holloway, RG
    Benesch, C
    Courtright, CE
    Rahilly, CR
    ANNALS OF NEUROLOGY, 1998, 44 (03) : 517 - 517
  • [6] Disparities in model-based cost-effectiveness analyses of tuberculosis diagnosis: A systematic review
    Padmasawitri, T. I. Armina
    Frederix, Gerardus W.
    Alisjahbana, Bachti
    Klungel, Olaf
    Hovels, Anke M.
    PLOS ONE, 2018, 13 (05):
  • [7] Experiences of Structured Elicitation for Model-Based Cost-Effectiveness Analyses
    Soares, Marta O.
    Sharples, Linda
    Morton, Alec
    Claxton, Karl
    Bojke, Laura
    VALUE IN HEALTH, 2018, 21 (06) : 715 - 723
  • [8] Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis
    G. B. Gomez
    D. W. Dowdy
    M. L. Bastos
    A. Zwerling
    S. Sweeney
    N. Foster
    A. Trajman
    M. A. Islam
    S. Kapiga
    E. Sinanovic
    G. M. Knight
    R. G. White
    W. A. Wells
    F. G. Cobelens
    A. Vassall
    BMC Infectious Diseases, 16
  • [9] Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis
    Gomez, G. B.
    Dowdy, D. W.
    Bastos, M. L.
    Zwerling, A.
    Sweeney, S.
    Foster, N.
    Trajman, A.
    Islam, M. A.
    Kapiga, S.
    Sinanovic, E.
    Knight, G. M.
    White, R. G.
    Wells, W. A.
    Cobelens, F. G.
    Vassall, A.
    BMC INFECTIOUS DISEASES, 2016, 16
  • [10] Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Lymphocytic Leukaemia: A Review of Methods to Model Disease Outcomes and Estimate Utility
    Kevin Marsh
    Peng Xu
    Panagiotis Orfanos
    James Gordon
    Ingolf Griebsch
    PharmacoEconomics, 2014, 32 : 981 - 993